Past PSI Events

Conferences

Journal Club - HTA and Safety Analyses

Our last event of 2014 was on HTA and Safety analyses. We were please to welcome speakers David Ohlssen and Chrissie Fletcher to discuss their respective papers.

CHAIR: TBC

SPEAKER: David Ohlssen (Novartis Pharmaceuticals Corporation)
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
Authors: Karen L. Price, H. Amy Xia, Hwanhee Hong, Jouni Kerman, Haoda Fu, George Quartey, Cory R. Heilmann, Haijun Ma and Bradley P. Carlin;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 55–70, January/February 2014
Abstract | Paper+ | Slides
 
SPEAKER: Christine Fletcher (Amgen Ltd)
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Authors: Christy Chuang-Stein, Marie-Ange Paget, Carol Reid and Neil Hawkins;
Pharmaceutical Statistics, Volume 13, Issue 4, Pages 265-274, July/August 2014
Abstract | Paper+ | Slides
 

+Papers available to view from 18th November 2014 to 16th December 2014

For a flier advertising the event, please click here.
 

Scientific Meetings

Journal Club - HTA and Safety Analyses

Our last event of 2014 was on HTA and Safety analyses. We were please to welcome speakers David Ohlssen and Chrissie Fletcher to discuss their respective papers.

CHAIR: TBC

SPEAKER: David Ohlssen (Novartis Pharmaceuticals Corporation)
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
Authors: Karen L. Price, H. Amy Xia, Hwanhee Hong, Jouni Kerman, Haoda Fu, George Quartey, Cory R. Heilmann, Haijun Ma and Bradley P. Carlin;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 55–70, January/February 2014
Abstract | Paper+ | Slides
 
SPEAKER: Christine Fletcher (Amgen Ltd)
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Authors: Christy Chuang-Stein, Marie-Ange Paget, Carol Reid and Neil Hawkins;
Pharmaceutical Statistics, Volume 13, Issue 4, Pages 265-274, July/August 2014
Abstract | Paper+ | Slides
 

+Papers available to view from 18th November 2014 to 16th December 2014

For a flier advertising the event, please click here.
 

Training Courses

Journal Club - HTA and Safety Analyses

Our last event of 2014 was on HTA and Safety analyses. We were please to welcome speakers David Ohlssen and Chrissie Fletcher to discuss their respective papers.

CHAIR: TBC

SPEAKER: David Ohlssen (Novartis Pharmaceuticals Corporation)
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
Authors: Karen L. Price, H. Amy Xia, Hwanhee Hong, Jouni Kerman, Haoda Fu, George Quartey, Cory R. Heilmann, Haijun Ma and Bradley P. Carlin;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 55–70, January/February 2014
Abstract | Paper+ | Slides
 
SPEAKER: Christine Fletcher (Amgen Ltd)
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Authors: Christy Chuang-Stein, Marie-Ange Paget, Carol Reid and Neil Hawkins;
Pharmaceutical Statistics, Volume 13, Issue 4, Pages 265-274, July/August 2014
Abstract | Paper+ | Slides
 

+Papers available to view from 18th November 2014 to 16th December 2014

For a flier advertising the event, please click here.
 

Journal Club

Journal Club - HTA and Safety Analyses

Our last event of 2014 was on HTA and Safety analyses. We were please to welcome speakers David Ohlssen and Chrissie Fletcher to discuss their respective papers.

CHAIR: TBC

SPEAKER: David Ohlssen (Novartis Pharmaceuticals Corporation)
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
Authors: Karen L. Price, H. Amy Xia, Hwanhee Hong, Jouni Kerman, Haoda Fu, George Quartey, Cory R. Heilmann, Haijun Ma and Bradley P. Carlin;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 55–70, January/February 2014
Abstract | Paper+ | Slides
 
SPEAKER: Christine Fletcher (Amgen Ltd)
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Authors: Christy Chuang-Stein, Marie-Ange Paget, Carol Reid and Neil Hawkins;
Pharmaceutical Statistics, Volume 13, Issue 4, Pages 265-274, July/August 2014
Abstract | Paper+ | Slides
 

+Papers available to view from 18th November 2014 to 16th December 2014

For a flier advertising the event, please click here.
 

Webinars

Journal Club - HTA and Safety Analyses

Our last event of 2014 was on HTA and Safety analyses. We were please to welcome speakers David Ohlssen and Chrissie Fletcher to discuss their respective papers.

CHAIR: TBC

SPEAKER: David Ohlssen (Novartis Pharmaceuticals Corporation)
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
Authors: Karen L. Price, H. Amy Xia, Hwanhee Hong, Jouni Kerman, Haoda Fu, George Quartey, Cory R. Heilmann, Haijun Ma and Bradley P. Carlin;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 55–70, January/February 2014
Abstract | Paper+ | Slides
 
SPEAKER: Christine Fletcher (Amgen Ltd)
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Authors: Christy Chuang-Stein, Marie-Ange Paget, Carol Reid and Neil Hawkins;
Pharmaceutical Statistics, Volume 13, Issue 4, Pages 265-274, July/August 2014
Abstract | Paper+ | Slides
 

+Papers available to view from 18th November 2014 to 16th December 2014

For a flier advertising the event, please click here.
 

Careers Meetings

Journal Club - HTA and Safety Analyses

Our last event of 2014 was on HTA and Safety analyses. We were please to welcome speakers David Ohlssen and Chrissie Fletcher to discuss their respective papers.

CHAIR: TBC

SPEAKER: David Ohlssen (Novartis Pharmaceuticals Corporation)
Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
Authors: Karen L. Price, H. Amy Xia, Hwanhee Hong, Jouni Kerman, Haoda Fu, George Quartey, Cory R. Heilmann, Haijun Ma and Bradley P. Carlin;
Pharmaceutical Statistics, Volume 13, Issue 1, Pages 55–70, January/February 2014
Abstract | Paper+ | Slides
 
SPEAKER: Christine Fletcher (Amgen Ltd)
Subgroup analyses in cost-effectiveness analyses to support health technology assessments
Authors: Christy Chuang-Stein, Marie-Ange Paget, Carol Reid and Neil Hawkins;
Pharmaceutical Statistics, Volume 13, Issue 4, Pages 265-274, July/August 2014
Abstract | Paper+ | Slides
 

+Papers available to view from 18th November 2014 to 16th December 2014

For a flier advertising the event, please click here.
 

Upcoming Events

PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data

Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.

PSI Journal Club: Survival Analysis

Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.

PSI VisSIG Webinar: Rapid Insights to Data

The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.

PSI One-Day Meeting: Non-proportional hazards and applications in immuno-oncology

Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.

Latest Jobs

Biostatistician Project Leader

As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.

Director Biostatistics

By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.

Director of Statistics

As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.